Company news

Axim Biotechnologies, Inc. (OTC:AXIM) news

Axim Biotechnologies, Inc. news releases on 6ix. Latest, Oct 6, 2026: AXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear…

Axim Biotechnologies, Inc. (OTC:AXIM) news

Press releases & updates

AXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear Lactoferrin Test for Dry Eye Disease

Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor

AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea

AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests

Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test

AXIM® Biotechnologies Receives Medical Device Manufacturing License

EQS-News: VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

EQS-News: AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch

AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit

AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays

AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing

AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance

AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent

AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions

AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch

AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022

AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

AXIM Biotechnologies CEO Issues Letter to Shareholders

AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease

AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test

AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19

AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board

AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19

AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board

AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development